Nowadays, the assessment of HER2 status and the selection of patients eligible for anti-HER2 therapy rely on IHC and in situ hybridization (ISH) on the primary tumor tissue according to the American Society of Clinical Oncology and the College of American Pathologists (ASCO/CAP) guidelines [6]. Here, ERBB2 is linked to neoplasm.